Jessica Snider, DO
Hematology & Oncology · Springfield, MONPI 1477760437
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,387 of the $1,647 with a category attached, or 84.2%. It is spread thinly across 23 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $756, 3.9 times the $195 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 71 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$298
- Novartis$229
- Medtronic$165
- Bristol Myers Squibb$130
- Genentech USA, Inc.$100
- GSK$99
- plus $627 from 17 others
Across 134 payments — averaging $2439.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$123K
- Genentech, Inc.$55K
- Puma Biotechnology, Inc.$44K
- AstraZeneca$44K
- Pharmacyclics LLC, An Abbvie Company$37K
- Amgen$18K
- plus $5K from 2 others
What the payments were for
- Food & beverage$1,38784%
- Education$26116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $298 |
| Novartis | 11 | $229 |
| Medtronic | 2 | $165 |
| Bristol Myers Squibb | 7 | $130 |
| Genentech USA, Inc. | 1 | $100 |
| GSK | 4 | $99 |
| Stemline Therapeutics Inc. | 2 | $91 |
| Johnson & Johnson | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Gilead | 2 | $48 |
| Amgen | 3 | $46 |
| Acrotech Biopharma Inc. | 3 | $42 |
| Tempus AI, Inc | 2 | $41 |
| Exelixis Inc. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $32 |
| AbbVie | 1 | $30 |
| AstraZeneca | 1 | $27 |
| Merck | 2 | $26 |
| Incyte Corporation | 1 | $23 |
| Sanofi | 1 | $22 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Eisai Inc. | 1 | $16 |
| Array Biopharma Inc | 1 | $12 |
How this compares
$1,647 in reported general payments places this provider in the 50th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 102 | $1,971,572 |
| RevlimidLenalidomide | 91 | $1,764,688 |
| JakafiRuxolitinib Phosphate | 60 | $876,715 |
| IbrancePalbociclib | 43 | $599,360 |
| XtandiEnzalutamide | 43 | $446,766 |
| BrukinsaZanubrutinib | 29 | $380,974 |
| VerzenioAbemaciclib | 18 | $285,218 |
| ScemblixAsciminib Hydrochloride | 12 | $261,876 |
| Lenalidomide | 17 | $226,430 |
| ErleadaApalutamide | 17 | $224,184 |
| SprycelDasatinib | 12 | $215,450 |
| TasignaNilotinib Hcl | 12 | $129,705 |
| CalquenceAcalabrutinib Maleate | 11 | $84,552 |
| EliquisApixaban | 45 | $27,154 |
| XareltoRivaroxaban | 30 | $19,045 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $33 | $1,971,572102 claims |
| Bristol Myers SquibbRevlimid | $130 | $1,764,68891 claims |
| Incyte CorporationJakafi | $23 | $876,71560 claims |
| PfizerIbrance, Eliquis | $298 | $626,51488 claims |
| Astellas Pharma US IncXtandi | $32 | $446,76643 claims |
| NovartisScemblix, Tasigna | $229 | $391,58124 claims |
| Johnson & JohnsonErleada, Xarelto | $66 | $243,22947 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $50 | $215,45012 claims |
| AstraZenecaCalquence, Nexium | $27 | $91,12223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Springfield
- Raymond LobinsSpringfield$22K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.